DSTYK amplification enables lung cancer cells to evade T cell killing by sustaining ULK1-dependent suppression of TNF-α-induced apoptosis. Targeting ULK1 dismantles this survival pathway, restoring RIPK1-mediated cell death and sensitizing DSTYK-altered tumors to chemo-immunotherapy, revealing a promising therapeutic vulnerability in NSCLC.